Therefore unlike the ITT analysis described previously, not all available patient data is utilised.
PCR primers were designed for 1954 genes of the A. pleuropneumoniae L20 (serovar 5b) genome using the Primer3 program [ 87] controlled by an automated script as described previously [make_primers code available at ] [ 88].
Plasmids used in the study that were described previously or commercially available: hVangl2-EGFP [ 34], xROR2-mCherry [ 35], β-arrestin-EGFP [ 36], mVangl2-HA [ 37], xCK1ε [ 38], hDvl3-flag [ 39], pDsRed-Monomer-Actin (Clontech), pmaxGFP (Lonza).
The FoxN1flox (fx) mice carrying a TM-inducible ubiquitous CreER (uCreERT), termed fx/fx-uCreERT were generated and genotyped as described previously and are available from Jackson Laboratories (Bar Harbor, ME, USA) (no. 012941).
ASCA were determined as described previously, employing commercially available ELISA (ASCA IgA, ASCA IgG, GA Generic Assays GmbH, Dahlewitz, Germany) according to the recommendations of the manufacturer as reported elsewhere [ 13].
Details about the design, the questionnaires, the data collection and consent procedures are described previously, and information is available at the web page of the Norwegian Institute of Public Health.
Genotyping was performed using single base primer extension and analyzed by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) on a Bruker III Daltonics Mass Spectrometer as described previously [ 39] (details available upon request).
Several oomycete EST databases described previously are no longer available, including the Syngenta Phytophthora Consortium (SPC) EST sequence data bases at https://xgi.ncgr.org/spc; the Phytophthora Functional Genomics Database at http://www.pfgd.org[ 8]; and ESTAP EST Analysis Pipelinee) [ 9] at http://staff.vbi.vt.edu/estap/.edu/estap/
Plasma BDNF levels were measured as described previously [22], using a commercially available ELISA kit (Promega) with the range of sensitivity from 7.8 to 500 pg/mL and inter-assay variation measured at 8.8% (low concentration), 2.9% (medium concentration) and 2.2% (high concentration).
Three thousand one hundred and twenty-nine healthy UK Caucasian control DNA samples were available as described previously.
